Bone Disease « « Myriad RBM
 
 

Bibliography

Bone Disease

2014

A Phase 2, Randomized, Double-blind, Multicenter Study Comparing Siltuximab Plus Best Supportive Care With Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1–Risk Myelodysplastic Syndrome (2014) Garcia-Manero G, Gartenberg G, Steensma DP, Schipperus MR, Breems DA, de Paz R, Valcárcel D, Kranenburg B, Reddy M, Komrokji RS Am J Hematol. 2014 May 31
 
Therapy Indications
 

Back To Top

2012

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis (2012) Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM N Engl J Med. 2012 Mar;366(9):799-807
 
Therapy Indications
 

Back To Top

2011

Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis (2011) Guglielmelli P, Barosi G, Rambaldi A, Marchioli R, Masciulli A, Tozzi L, Biamonte F, Bartalucci N, Gattoni E, Lupo ML, Finazzi G, Pancrazzi A, Antonioli E, Susini MC, Pieri L, Malevolti E, Usala E, Occhini U, Grossi A, Caglio S, Paratore S, Bosi A, Barbui T, Vannucchi AM Blood. 2011 Jul 1. [Epub ahead of print]
 
Product Associations
 
 
Therapy Indications
 

Back To Top

2010

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis (2010) Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A N Engl J Med. 363: 1117-27.
 
Product Associations
 
 
Therapy Indications